Form 4: Day One Biopharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Director J. Scott Garland acquired 32,335 stock options in Day One Biopharmaceuticals on May 23, 2024, according to a Form 4 filing.
Summary
- On May 23, 2024, J. Scott Garland, a director of Day One Biopharmaceuticals, Inc. (DAWN), acquired 32,335 stock options.
- The options have an exercise price of $13.87.
- The options vest monthly, starting June 23, 2024, and expire on May 22, 2034.
- The transaction was reported in a Form 4 filing with the SEC.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to stock option grants, so the sentiment is neutral.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like directors and officers, trade their company's securities. This provides transparency to the market.
Stakeholder Impact
- The acquisition of stock options by a director could signal confidence in the company's future prospects to shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/23/2024 | Date of transaction: J. Scott Garland acquired stock options. |
| 06/23/2024 | Vesting start date: Options vest monthly, beginning on this date. |
| 05/22/2034 | Expiration date: Options expire on this date. |
| 05/28/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.